The Evolution and Future of Targeted Cancer Therapy: From Nanoparticles, Oncolytic Viruses, and Oncolytic Bacteria to the Treatment of Solid Tumors

While many classes of chemotherapeutic agents exist to treat solid tumors, few can generate a lasting response without substantial off-target toxicity despite significant scientific advancements and investments. In this review, the paths of development for nanoparticles, oncolytic viruses, and oncol...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kyle M. Pierce, William R. Miklavcic, Kyle P. Cook, Mikayla Sweitzer Hennen, Kenneth W. Bayles, Michael A. Hollingsworth, Amanda E. Brooks, Jessica E. Pullan, Kaitlin M. Dailey
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	nanoparticles oncolytic viruses oncolytic bacteria exosomes clinical trials solid tumors Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/c19bdbb1ecd94538b9ccb4e277118948
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c19bdbb1ecd94538b9ccb4e277118948
record_format	dspace
spelling	oai:doaj.org-article:c19bdbb1ecd94538b9ccb4e2771189482021-11-25T18:31:47ZThe Evolution and Future of Targeted Cancer Therapy: From Nanoparticles, Oncolytic Viruses, and Oncolytic Bacteria to the Treatment of Solid Tumors10.3390/nano111130182079-4991https://doaj.org/article/c19bdbb1ecd94538b9ccb4e2771189482021-11-01T00:00:00Zhttps://www.mdpi.com/2079-4991/11/11/3018https://doaj.org/toc/2079-4991While many classes of chemotherapeutic agents exist to treat solid tumors, few can generate a lasting response without substantial off-target toxicity despite significant scientific advancements and investments. In this review, the paths of development for nanoparticles, oncolytic viruses, and oncolytic bacteria over the last 20 years of research towards clinical translation and acceptance as novel cancer therapeutics are compared. Novel nanoparticle, oncolytic virus, and oncolytic bacteria therapies all start with a common goal of accomplishing therapeutic drug activity or delivery to a specific site while avoiding off-target effects, with overlapping methodology between all three modalities. Indeed, the degree of overlap is substantial enough that breakthroughs in one therapeutic could have considerable implications on the progression of the other two. Each oncotherapeutic modality has accomplished clinical translation, successfully overcoming the potential pitfalls promising therapeutics face. However, once studies enter clinical trials, the data all but disappears, leaving pre-clinical researchers largely in the dark. Overall, the creativity, flexibility, and innovation of these modalities for solid tumor treatments are greatly encouraging, and usher in a new age of pharmaceutical development.Kyle M. PierceWilliam R. MiklavcicKyle P. CookMikayla Sweitzer HennenKenneth W. BaylesMichael A. HollingsworthAmanda E. BrooksJessica E. PullanKaitlin M. DaileyMDPI AGarticlenanoparticlesoncolytic virusesoncolytic bacteriaexosomesclinical trialssolid tumorsChemistryQD1-999ENNanomaterials, Vol 11, Iss 3018, p 3018 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	nanoparticles oncolytic viruses oncolytic bacteria exosomes clinical trials solid tumors Chemistry QD1-999
spellingShingle	nanoparticles oncolytic viruses oncolytic bacteria exosomes clinical trials solid tumors Chemistry QD1-999 Kyle M. Pierce William R. Miklavcic Kyle P. Cook Mikayla Sweitzer Hennen Kenneth W. Bayles Michael A. Hollingsworth Amanda E. Brooks Jessica E. Pullan Kaitlin M. Dailey The Evolution and Future of Targeted Cancer Therapy: From Nanoparticles, Oncolytic Viruses, and Oncolytic Bacteria to the Treatment of Solid Tumors
description	While many classes of chemotherapeutic agents exist to treat solid tumors, few can generate a lasting response without substantial off-target toxicity despite significant scientific advancements and investments. In this review, the paths of development for nanoparticles, oncolytic viruses, and oncolytic bacteria over the last 20 years of research towards clinical translation and acceptance as novel cancer therapeutics are compared. Novel nanoparticle, oncolytic virus, and oncolytic bacteria therapies all start with a common goal of accomplishing therapeutic drug activity or delivery to a specific site while avoiding off-target effects, with overlapping methodology between all three modalities. Indeed, the degree of overlap is substantial enough that breakthroughs in one therapeutic could have considerable implications on the progression of the other two. Each oncotherapeutic modality has accomplished clinical translation, successfully overcoming the potential pitfalls promising therapeutics face. However, once studies enter clinical trials, the data all but disappears, leaving pre-clinical researchers largely in the dark. Overall, the creativity, flexibility, and innovation of these modalities for solid tumor treatments are greatly encouraging, and usher in a new age of pharmaceutical development.
format	article
author	Kyle M. Pierce William R. Miklavcic Kyle P. Cook Mikayla Sweitzer Hennen Kenneth W. Bayles Michael A. Hollingsworth Amanda E. Brooks Jessica E. Pullan Kaitlin M. Dailey
author_facet	Kyle M. Pierce William R. Miklavcic Kyle P. Cook Mikayla Sweitzer Hennen Kenneth W. Bayles Michael A. Hollingsworth Amanda E. Brooks Jessica E. Pullan Kaitlin M. Dailey
author_sort	Kyle M. Pierce
title	The Evolution and Future of Targeted Cancer Therapy: From Nanoparticles, Oncolytic Viruses, and Oncolytic Bacteria to the Treatment of Solid Tumors
title_short	The Evolution and Future of Targeted Cancer Therapy: From Nanoparticles, Oncolytic Viruses, and Oncolytic Bacteria to the Treatment of Solid Tumors
title_full	The Evolution and Future of Targeted Cancer Therapy: From Nanoparticles, Oncolytic Viruses, and Oncolytic Bacteria to the Treatment of Solid Tumors
title_fullStr	The Evolution and Future of Targeted Cancer Therapy: From Nanoparticles, Oncolytic Viruses, and Oncolytic Bacteria to the Treatment of Solid Tumors
title_full_unstemmed	The Evolution and Future of Targeted Cancer Therapy: From Nanoparticles, Oncolytic Viruses, and Oncolytic Bacteria to the Treatment of Solid Tumors
title_sort	evolution and future of targeted cancer therapy: from nanoparticles, oncolytic viruses, and oncolytic bacteria to the treatment of solid tumors
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/c19bdbb1ecd94538b9ccb4e277118948
work_keys_str_mv	AT kylempierce theevolutionandfutureoftargetedcancertherapyfromnanoparticlesoncolyticvirusesandoncolyticbacteriatothetreatmentofsolidtumors AT williamrmiklavcic theevolutionandfutureoftargetedcancertherapyfromnanoparticlesoncolyticvirusesandoncolyticbacteriatothetreatmentofsolidtumors AT kylepcook theevolutionandfutureoftargetedcancertherapyfromnanoparticlesoncolyticvirusesandoncolyticbacteriatothetreatmentofsolidtumors AT mikaylasweitzerhennen theevolutionandfutureoftargetedcancertherapyfromnanoparticlesoncolyticvirusesandoncolyticbacteriatothetreatmentofsolidtumors AT kennethwbayles theevolutionandfutureoftargetedcancertherapyfromnanoparticlesoncolyticvirusesandoncolyticbacteriatothetreatmentofsolidtumors AT michaelahollingsworth theevolutionandfutureoftargetedcancertherapyfromnanoparticlesoncolyticvirusesandoncolyticbacteriatothetreatmentofsolidtumors AT amandaebrooks theevolutionandfutureoftargetedcancertherapyfromnanoparticlesoncolyticvirusesandoncolyticbacteriatothetreatmentofsolidtumors AT jessicaepullan theevolutionandfutureoftargetedcancertherapyfromnanoparticlesoncolyticvirusesandoncolyticbacteriatothetreatmentofsolidtumors AT kaitlinmdailey theevolutionandfutureoftargetedcancertherapyfromnanoparticlesoncolyticvirusesandoncolyticbacteriatothetreatmentofsolidtumors AT kylempierce evolutionandfutureoftargetedcancertherapyfromnanoparticlesoncolyticvirusesandoncolyticbacteriatothetreatmentofsolidtumors AT williamrmiklavcic evolutionandfutureoftargetedcancertherapyfromnanoparticlesoncolyticvirusesandoncolyticbacteriatothetreatmentofsolidtumors AT kylepcook evolutionandfutureoftargetedcancertherapyfromnanoparticlesoncolyticvirusesandoncolyticbacteriatothetreatmentofsolidtumors AT mikaylasweitzerhennen evolutionandfutureoftargetedcancertherapyfromnanoparticlesoncolyticvirusesandoncolyticbacteriatothetreatmentofsolidtumors AT kennethwbayles evolutionandfutureoftargetedcancertherapyfromnanoparticlesoncolyticvirusesandoncolyticbacteriatothetreatmentofsolidtumors AT michaelahollingsworth evolutionandfutureoftargetedcancertherapyfromnanoparticlesoncolyticvirusesandoncolyticbacteriatothetreatmentofsolidtumors AT amandaebrooks evolutionandfutureoftargetedcancertherapyfromnanoparticlesoncolyticvirusesandoncolyticbacteriatothetreatmentofsolidtumors AT jessicaepullan evolutionandfutureoftargetedcancertherapyfromnanoparticlesoncolyticvirusesandoncolyticbacteriatothetreatmentofsolidtumors AT kaitlinmdailey evolutionandfutureoftargetedcancertherapyfromnanoparticlesoncolyticvirusesandoncolyticbacteriatothetreatmentofsolidtumors
_version_	1718411041136705536

The Evolution and Future of Targeted Cancer Therapy: From Nanoparticles, Oncolytic Viruses, and Oncolytic Bacteria to the Treatment of Solid Tumors

Ejemplares similares